Precigen strategically prioritizes portfolio to focus on first potential gene therapy launch

– prgn-2012 is on track for a rolling bla submission under an accelerated approval pathway; patient enrollment initiated in the confirmatory clinical trial – germantown, md. , aug. 6, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced a strategic reprioritization of the company's clinical portfolio and streamlining of resources, including a reduction of over 20% of its workforce, to focus on potential commercialization of the prgn-2012 adenoverse ®  gene therapy for the treatment of recurrent respiratory papillomatosis (rrp).
PGEN Ratings Summary
PGEN Quant Ranking